We are live on ! Find out more
PCSA icon

Processa Pharmaceuticals
PCSA

16 hedge funds and large institutions have $3.22M invested in Processa Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 16 → 16 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

1.64% less ownership

Funds ownership: 8.4% → 6.76% (-1.6%)

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

98% less capital inflows, than outflows

Capital inflows: $20.9K | Capital outflows: $1.05M

Holders
16
Holders Change
–
Holders Change %
0%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Wells Fargo
Wells Fargo
California
+$11.4K
2
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
+$5.71K
3
UBS Group
UBS Group
Switzerland
+$3.81K

Top Sellers

Rank Fund Capital Flow
1
Solas Capital Management
Solas Capital Management
Connecticut
-$659K
2
Essex Investment Management
Essex Investment Management
Massachusetts
-$359K
3
Vectors Research Management
Vectors Research Management
New York
-$20K
4
Verdence Capital Advisors
Verdence Capital Advisors
Maryland
-$11.4K
5
BlackRock
BlackRock
New York
-$5.71K

PCSA Hedge Fund Activity: Q1 2022 in Review

16 of the 6,363 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q1 2022, worth a combined $3.22M — down 50% from $6.47M a quarter earlier.

Fund positioning in PCSA was balanced in Q1 2022: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 3 trimmed.

The largest buyer was Wells Fargo, opening a new position worth an estimated $11.4K. The largest seller was Solas Capital Management, cutting an estimated $659K.

  • 16 institutional investors held Processa Pharmaceuticals (PCSA) as of Q1 2022, unchanged from Q4 2021.
  • Funds reported $3.22M of Processa Pharmaceuticals stock for Q1 2022, down 50% quarter-over-quarter.
  • 2 funds opened new Processa Pharmaceuticals positions in Q1 2022 and 2 closed out, a net change of 0 holders.
  • The largest Processa Pharmaceuticals buyer in Q1 2022 was Wells Fargo, an estimated $11.4K added.
  • The largest Processa Pharmaceuticals seller in Q1 2022 was Solas Capital Management, an estimated $659K sold.

Based on aggregated 13F filings for Q1 2022.